EC Number   |
|---|
    2.7.1.74 | crystal structure model construction, using the crystal structure of deoxyguanosine kinase, EC 2.7.1.113, as a template, for docking simulations of enzyme with purine nucleosides and analogues, overview |
| 2.7.1.74 | dCK in complex with acyclovir at the nucleoside phosphoryl acceptor site, and UDP at the phosphoryl donor site, hanging drop vapour diffusion method, 20 mg/ml protein with 5 mM UDP and 5 mM acyclovir is mixed with reservoir solution containing 0.90-1.5 M trisodium citrate dihydrate and 100 mM HEPES, pH 7.5, 12°C, X-ray diffraction structure determination and analysis at 2.1 A resolution, molecular replacement |
| 2.7.1.74 | enzyme mutant C9S/C45S/C59S/S74E/R104M/D133A/C146S in complex with L-dT and UDP, hanging drop vapour diffusion method, mixing of 0.001 ml of 9-15 mg/ml protein mixed with 0.001 ml reservoir solution containing 0.9-1.5 M trisodium citrate dihydrate and 100 mM Tris, pH 7.5, room temperature, X-ray diffraction structure determination and analysis at 1.9-2.5 A resolution |
| 2.7.1.74 | hanging drop vapour diffusion method, in complex with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine and ADP |
| 2.7.1.74 | hanging drop vapour diffusion method, in complex with deoxycytidine (dC) and UDP, and in the presence of deoxycytidine but the absence of UDP or ADP |
| 2.7.1.74 | hanging drop vapour diffusion method, mutant enzyme crystallized in complex with its substrates (-)-beta-2,3-dideoxy-3-thiacytidine and troxacitabine |
| 2.7.1.74 | in complex with 5-methyldeoxycytidine and ADP, hanging drop vapor diffusion method |
| 2.7.1.74 | in complex with dCMP, UDP, and Mg2+ ion, as well as with dAMP, UDP and Mg2+ ion, both to 3.4 A resolution. Product complexes with UDP and a dead-end complex with substrate and UDP have similar active-site conformations |
| 2.7.1.74 | in complex with inhibitors 2-(((2-(3-(2-fluoroethoxy)-4-methoxyphenyl)-5-methylthiazol-4-yl)methyl)thio)pyrimidine-4,6-diamine and 1-(5-(4-(((4,6-diaminopyrimidin-2-yl)thio)methyl)-5-propylthiazol-2-yl)-2-methoxyphenoxy)-2-methylpropan-2-ol , hanging drop vapor diffusion method, using 0.9-1.5 M trisodium citrate dehydrate and 25 mM HEPES (pH 7.5), at 12°C |
| 2.7.1.74 | in complex with inhibitors and UDP, hanging drop vapor diffusion method, using 0.9-1.5 M trisodium citrate dehydrate and 25 mM HEPES pH 7.5 |
